GlassScriptPhysician profile
Yoon Kook Kim
NPI 1205332038
$2,478.11
in general payments reported to CMS, 2019-2025
28 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.81 · 2023: $858 · 2024: $1,046 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $245.57 | 2023-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $216.57 | 2023-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $186.71 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $166.52 | 2023-2025 | Tymlos |
| Amgen INC. | $164.43 | 2023-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $162.66 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $147.50 | 2024-2025 | |
| Novo Nordisk INC | $133.92 | 2023-2025 | Rybelsus, Ozempic, Sogroya |
| Xeris Pharmaceuticals, INC. | $125.37 | 2023 | Recorlev |
| Alexion Pharmaceuticals, INC. | $98.24 | 2023-2024 | Strensiq |
| Mannkind Corporation | $92.81 | 2023-2024 | Afrezza |
| Insulet Corporation | $90.74 | 2024-2025 | Omnipod |
| Abbvie INC. | $85.36 | 2024-2025 | |
| Medtronic, INC. | $82.80 | 2024-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $62.12 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $56.08 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.72 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Averitas Pharma INC. | $50.39 | 2024 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $43.81 | 2022 | |
| Antares Pharma, INC. | $39.91 | 2024-2025 | Xyosted |
| Recordati_rare_diseases_inc. | $30.87 | 2023-2025 | Isturisa, Signifor Lar |
| Almatica Pharma LLC | $27.57 | 2024 | Teriparatide |
| Pfizer INC. | $25.54 | 2025 | |
| Ibsa Pharma INC. | $21.67 | 2024 | Licart, Tirosint |
| Halozyme INC | $20.26 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.39 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.75 | 2024 | Evkeeza |
| Tolmar, INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoon Kook Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.